Intratympanic Injections of N-acetylcysteine and Dexamethasone for Prevention of Cisplatin-induced Ototoxicity: Double Blind Randomized Clinical Trial

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

TCTR

Registry ID

TCTR20160314003

Enrollment

Unknown

Registered

2016-03-14

Start date

2013-02-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hearing impairment Hearing Loss Intratympanic Injection Dexamethasone Acetylcysteine

Interventions

intratympanic injection of N&#45

acetylcysteine (10%) ,intratympanic injection of Dexamethasone

Active Comparator Drug,Active Comparator Drug

N&#45

acetylcysteine,Dexamethasone

Eligibility

Sex/Gender

All

Age

6 Years to 60 Years

Inclusion criteria

Inclusion criteria: first cycle of cisplatin therapy normal tympanogram type A normal microscopic examinations no history of head trauma, brain tumors, severe ear infection, ear surgery, ruptured eardrums, meningoencephalitis, acoustic trauma and cranial radiation

Exclusion criteria

Exclusion criteria: Patients in the end stages of cancers or taking other ototoxic drugs

Design outcomes

Primary

Measure	Time frame
hearing impairment before each cycle of cisplatin therapy pure tone audiometry	—

Secondary

Measure	Time frame
hearing impairment 6 months after the last cycle of cisplatin therapy pure tone audiometry	—

Countries

Iran

Contacts

Public ContactMohammad Hossein Azaraein

Student Research Committee, Shahid Sadoughi University of Medical Sciences-Yazd, Iran

mh.azaraein@yahoo.com00989132560656

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026

Intratympanic Injections of N&#45;acetylcysteine and Dexamethasone for Prevention of Cisplatin&#45;induced Ototoxicity: Double Blind Randomized Clinical Trial